WEBSITE BSE:524470 NSE: SYNCOM FORM. Inc. Year: 1988 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:56
No Notes Added Yet
Syncom Formulations (India) Ltd is a pharmaceutical organisation. The Company manufactures and markets over 300 pharmaceutical formulations merchandise in diverse dosage forms, including tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments, inhalers and herbals. It exports various commodities, including pharmaceutical, which include active pharmaceutical ingredients (APIs) and surgical merchandise; agro and confectionary products, such as rice, wheat flour, chickpeas, soy de oiled c...Read More
Syncom Formulations (India) Ltd is a pharmaceutical organisation. The Company manufactures and markets over 300 pharmaceutical formulations merchandise in diverse dosage forms, including tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments, inhalers and herbals. It exports various commodities, including pharmaceutical, which include active pharmaceutical ingredients (APIs) and surgical merchandise; agro and confectionary products, such as rice, wheat flour, chickpeas, soy de oiled cake, biscuits and sweets, and business products, which includes fasteners, metal bars, roofing sheets and jute baggage, and steel scrap. The Company's division, Cratus Life Care, is concerned in looking after domestic marketplace's desires. Its antifungal merchandise consist of Fluconazole Tablets 150 (mg), Itrakonazole Tablets 100 mg, Furazolidone Capsules 100 mg and Itraconazole Capsules 100 mg. Its production facility is positioned at Pithampur, Madhya Pradesh. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹1308 Cr.
Stock P/E 26.4
P/B 3.3
Current Price ₹13.9
Book Value ₹ 4.2
Face Value 1
52W High ₹23.5
Dividend Yield 0%
52W Low ₹ 10.2
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 64 | 65 | 75 | 87 | 102 | 128 | 149 | 117 | 122 | 115 |
| Other Income | 4 | 5 | 3 | 1 | 4 | 4 | 7 | 6 | 5 | 6 |
| Total Income | 68 | 70 | 78 | 89 | 106 | 132 | 156 | 123 | 127 | 121 |
| Total Expenditure | 57 | 58 | 65 | 77 | 90 | 113 | 131 | 101 | 103 | 94 |
| Operating Profit | 10 | 12 | 13 | 12 | 16 | 19 | 25 | 22 | 24 | 27 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 8 | 9 | 10 | 10 | 15 | 17 | 23 | 20 | 22 | 25 |
| Provision for Tax | 2 | 2 | 3 | 2 | 4 | 4 | 6 | 5 | 5 | 6 |
| Profit After Tax | 7 | 7 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 |
| Adjustments | 0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | 7 | 7 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 |
| Adjusted Earnings Per Share | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 115 | 151 | 173 | 184 | 185 | 220 | 224 | 263 | 465 | 503 |
| Other Income | 1 | 1 | 2 | 3 | 3 | 12 | 15 | 14 | 17 | 24 |
| Total Income | 116 | 152 | 175 | 187 | 188 | 232 | 239 | 277 | 482 | 527 |
| Total Expenditure | 104 | 135 | 155 | 167 | 168 | 200 | 204 | 234 | 411 | 429 |
| Operating Profit | 12 | 17 | 20 | 19 | 19 | 32 | 34 | 43 | 72 | 98 |
| Interest | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 1 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 4 |
| Exceptional Income / Expenses | 0 | -0 | -1 | -0 | -0 | 0 | 0 | -0 | 0 | 0 |
| Profit Before Tax | 8 | 14 | 16 | 16 | 16 | 26 | 27 | 34 | 66 | 90 |
| Provision for Tax | 3 | 5 | 6 | 6 | 5 | 6 | 7 | 9 | 16 | 22 |
| Profit After Tax | 6 | 9 | 10 | 10 | 11 | 20 | 20 | 25 | 49 | 70 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 6 | 9 | 10 | 10 | 11 | 20 | 20 | 25 | 49 | 70 |
| Adjusted Earnings Per Share | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.5 | 0.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 77% | 28% | 20% | 0% |
| Operating Profit CAGR | 67% | 31% | 31% | 0% |
| PAT CAGR | 96% | 35% | 37% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -18% | 32% | 19% | 20% |
| ROE Average | 16% | 11% | 11% | 10% |
| ROCE Average | 19% | 13% | 13% | 14% |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 88 | 95 | 100 | 109 | 117 | 222 | 256 | 288 | 342 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 8 | 7 | 6 | 6 | 8 | 8 | 9 | 10 | 12 |
| Total Current Liabilities | 28 | 42 | 37 | 66 | 59 | 78 | 113 | 109 | 62 |
| Total Liabilities | 124 | 144 | 143 | 181 | 184 | 308 | 378 | 407 | 416 |
| Fixed Assets | 50 | 50 | 46 | 46 | 55 | 47 | 43 | 72 | 78 |
| Other Non-Current Assets | 12 | 15 | 13 | 43 | 42 | 122 | 153 | 57 | 66 |
| Total Current Assets | 62 | 78 | 84 | 92 | 87 | 140 | 182 | 277 | 272 |
| Total Assets | 124 | 144 | 143 | 181 | 184 | 308 | 378 | 407 | 416 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 5 | 4 | 5 | 7 | 6 | 3 | 0 | 1 | 63 |
| Cash Flow from Operating Activities | 6 | 7 | 0 | 24 | 14 | 16 | 11 | -6 | 23 |
| Cash Flow from Investing Activities | -0 | -4 | 1 | -23 | -18 | -27 | -45 | 83 | -18 |
| Cash Flow from Financing Activities | -6 | -1 | 1 | -2 | 5 | 8 | 35 | -15 | -68 |
| Net Cash Inflow / Outflow | -1 | 2 | 1 | -1 | 1 | -2 | 1 | 63 | -63 |
| Closing Cash & Cash Equivalent | 4 | 5 | 7 | 6 | 7 | 0 | 1 | 63 | 1 |
| # | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.07 | 0.12 | 0.13 | 0.13 | 0.13 | 0.23 | 0.21 | 0.27 | 0.53 |
| CEPS(Rs) | 0.11 | 0.16 | 0.17 | 0.17 | 0.17 | 0.28 | 0.26 | 0.32 | 0.58 |
| DPS(Rs) | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 1.12 | 1.22 | 1.28 | 1.39 | 1.5 | 2.52 | 2.72 | 3.07 | 3.64 |
| Core EBITDA Margin(%) | 9.27 | 10.73 | 10.5 | 8.98 | 8.96 | 9.12 | 8.87 | 11.26 | 11.64 |
| EBIT Margin(%) | 7.81 | 9.49 | 9.18 | 8.75 | 8.77 | 12.79 | 13.37 | 14.59 | 14.27 |
| Pre Tax Margin(%) | 7.35 | 9.18 | 9.01 | 8.68 | 8.59 | 11.92 | 11.85 | 12.89 | 14.09 |
| PAT Margin (%) | 4.92 | 6.14 | 5.62 | 5.58 | 5.7 | 9.01 | 8.95 | 9.61 | 10.63 |
| Cash Profit Margin (%) | 7.38 | 8.12 | 7.58 | 7.2 | 7.39 | 10.81 | 10.97 | 11.4 | 11.75 |
| ROA(%) | 4.54 | 6.95 | 6.82 | 6.41 | 5.78 | 8.04 | 5.85 | 6.45 | 12.02 |
| ROE(%) | 6.45 | 10.19 | 9.99 | 9.91 | 9.32 | 11.83 | 8.48 | 9.3 | 15.69 |
| ROCE(%) | 10 | 15.29 | 15.55 | 14.72 | 13.28 | 13.72 | 9.68 | 10.98 | 18.77 |
| Receivable days | 91.86 | 70.22 | 63.71 | 75.88 | 90.83 | 94.33 | 116.42 | 123.89 | 82.75 |
| Inventory Days | 19.28 | 19.22 | 21.92 | 25.97 | 25.15 | 24.52 | 33.13 | 29.3 | 24.5 |
| Payable days | 118.99 | 117.59 | 106.53 | 114.53 | 140.62 | 79.52 | 62.08 | 69.17 | 45.68 |
| PER(x) | 29.91 | 48.62 | 34.32 | 16.8 | 14.6 | 46.32 | 27.63 | 41.52 | 31.28 |
| Price/Book(x) | 1.93 | 4.76 | 3.34 | 1.6 | 1.31 | 4.22 | 2.17 | 3.65 | 4.52 |
| Dividend Yield(%) | 0.79 | 0.34 | 0.47 | 0.9 | 1.02 | 0.28 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.46 | 2.98 | 1.93 | 0.95 | 0.86 | 4.43 | 2.81 | 4.01 | 3.33 |
| EV/Core EBITDA(x) | 14.2 | 25.92 | 16.56 | 9 | 8.26 | 30.42 | 18.24 | 24.45 | 21.66 |
| Net Sales Growth(%) | 0 | 31.61 | 14.61 | 6.06 | 0.5 | 18.85 | 2.09 | 17.45 | 76.55 |
| EBIT Growth(%) | 0 | 60.4 | 10.64 | 1.95 | -0.16 | 73.35 | 6.66 | 28.2 | 72.74 |
| PAT Growth(%) | 0 | 64.72 | 4.72 | 6.14 | 1.72 | 87.87 | 1.42 | 26.13 | 95.28 |
| EPS Growth(%) | 0 | 64.55 | 4.78 | 6.16 | 1.66 | 70.13 | -6.97 | 26.14 | 95.28 |
| Debt/Equity(x) | 0.02 | 0.03 | 0.06 | 0.05 | 0.11 | 0.27 | 0.32 | 0.25 | 0.01 |
| Current Ratio(x) | 2.18 | 1.88 | 2.28 | 1.4 | 1.47 | 1.79 | 1.61 | 2.55 | 4.41 |
| Quick Ratio(x) | 1.96 | 1.64 | 1.98 | 1.16 | 1.3 | 1.54 | 1.42 | 2.35 | 3.74 |
| Interest Cover(x) | 17.1 | 30.75 | 54.58 | 119.1 | 48.48 | 14.58 | 8.81 | 8.59 | 76.75 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | 0.02 | 0.03 | 0.08 | 0.06 | 0.15 | 0.07 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 |
| FII | 0 | 0.08 | 0.09 | 0.1 | 0.13 | 0.11 | 0.41 | 0.1 | 0.26 | 0.21 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 49.43 | 49.35 | 49.34 | 49.33 | 49.3 | 49.32 | 49.02 | 49.33 | 49.17 | 49.21 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 47.53 | 47.53 | 47.53 | 47.53 | 47.53 | 47.53 | 47.53 | 47.53 | 47.53 | 47.53 |
| FII | 0 | 0.07 | 0.08 | 0.1 | 0.12 | 0.1 | 0.38 | 0.09 | 0.25 | 0.2 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 46.46 | 46.39 | 46.38 | 46.37 | 46.34 | 46.36 | 46.08 | 46.37 | 46.22 | 46.26 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 94 | 94 | 94 | 94 | 94 | 94 | 94 | 94 | 94 | 94 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
